Growing recognition of the pro-oncogenic influence, which MDM2 and MDMX have in promoting cancer survival and metastasis, independent of p53, exemplifies the urgent unmet need for novel therapeutic approaches to exploiting MDM2 and MDMX activity.1 The gene discussed is TP53; the disease is cancer.